Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.45 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.45 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.41 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29886954 | 1.00 | MAPT (0.50) | MAPTFDPSALDH1A1SMN1; SMN2HTT | |
| SCHEMBL24925872 | 0.87 | FDPS (0.50) | MAPTFDPSALDH1A1SMN1; SMN2HTT | |
| SCHEMBL29886959 | 0.87 | FDPS (0.50) | MAPTFDPSALDH1A1SMN1; SMN2HTT | |
| SCHEMBL2552700 | 0.86 | FDPS (0.48) | MAPTFDPSALDH1A1SMN1; SMN2HTT | |
| SCHEMBL4959651 | 0.85 | FDPS (0.61) | MAPTFDPSALDH1A1SMN1; SMN2HTT | |
| SCHEMBL29655033 | 0.85 | FDPS (0.61) | MAPTFDPSALDH1A1SMN1; SMN2HTT | |
| SCHEMBL4255761 | 0.84 | FDPS (0.64) | MAPTFDPSALDH1A1SMN1; SMN2HTT | |
| SCHEMBL31160627 | 0.84 | FDPS (0.64) | MAPTFDPSALDH1A1SMN1; SMN2HTT | |
| SCHEMBL23143191 | 0.83 | MAPT (0.47) | MAPTALDH1A1SMN1; SMN2HTTNPC1 | |
| SCHEMBL493460 | 0.83 | ALDH1A1 (0.60) | MAPTFDPSALDH1A1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629382-B2 | Therapy | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2026-05-19 | — | — | US | disclosed |
| EP-4733299-A1 | SULFUR-CONTAINING FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen Braegen Pharmaceutical Co., Ltd. (CN) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024240186-A1 | SULFUR-CONTAINING FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳博芮健制药有限公司 | 2024-11-28 | — | — | WO | disclosed |
| US-11844846-B2 | Styrylbenzothiazole derivatives and uses in imaging methods | EMORY UNIVERSITY (US) | 2023-12-19 | — | — | US | disclosed |
| CN-114981251-B | Dibenzofuran derivative cathepsin K inhibitor and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| WO-2023180813-A1 | NARINGENIN OR DERIVATIVES THEREOF FOR IMPROVING SKELETAL MUSCLE ENDURANCE OR FOR TREATING OR PREVENTING MUSCLE ATROPHY OR DYSTROPHY | INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2023-09-28 | — | — | WO | disclosed |
| US-20220362265-A1 | THERAPY | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2022-11-17 | — | — | US | disclosed |
| CN-114981251-A | Diphenyl furan derivative cathepsin K inhibitor and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| EP-4021504-A1 | THERAPY | Vestlandets Innovasjonsselskap AS (NO) | 2022-07-06 | — | — | EP | disclosed |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2021-11-25 | — | — | US | disclosed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
| CN-1269788-C | Bicyclic aromatic compounds and their use in human or veterinary medicine and in cosmetic processes | GALDERMA RES DEV S N C (FR) | 2006-08-16 | — | — | CN | disclosed |
| US-6924388-B2 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-02 | — | — | US | disclosed |
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-05-13 | — | — | US | disclosed |
| US-6632963-B1 | Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2003-10-14 | — | — | US | disclosed |
| EP-0947496-B1 | Bicyclic aromatic compounds and their use in human and veterinary medicine as well as in cosmetology | GALDERMA RES & DEV (FR) | 2002-10-09 | — | — | EP | disclosed |
| CN-1346828-A | Dicyclic aromatic compound and use thereof in human or animal medicine and cosmetic process | CT INTERNAT DE RES ES DERMATOL (FR) | 2002-05-01 | — | — | CN | disclosed |
| CN-1241558-A | Bicyclic aromatic compounds and their use in human or veterinary medicine and in cosmetic processes | GALDERMA RESEARCH DEV S N C (FR) | 2000-01-19 | — | — | CN | disclosed |
| EP-0947496-A1 | Bicyclic aromatic compounds and their use in human and veterinary medicine as well as in cosmetology | Galderma Research & Development, S.N.C. (FR) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | MAPT 3436/4885FDPS 948/4885ALDH1A1 548/4885 |
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | AHR, TYR, MC1R | MAPT 2429/4885FDPS 3696/4885ALDH1A1 88/4885 |
| US-12629382-B2 | Therapy | NR3C1, MGMT, GRM3 | MAPT 4450/4885FDPS 3500/4885ALDH1A1 338/4885 |
| US-11844846-B2 | Styrylbenzothiazole derivatives and uses in imaging methods | SNCA, NLN, SMN1; SMN2 | MAPT 38/4885FDPS 4007/4885ALDH1A1 1535/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | MAPT 3320/4885FDPS 3084/4885ALDH1A1 1784/4885 |
| US-20220362265-A1 | THERAPY | GRM3, GLRX3, CBR3 | MAPT 4429/4885FDPS 2834/4885ALDH1A1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.